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Summary We conducted a phase I study of irinotecan (CPT-11) and etoposide (VP-16) given sequentially to untreated patients with
metastatic non-small-cell lung cancer. Arm A: CPT-11 was given over90 min on days 1-3 and VP-16 was given over60 min on days 4-6. Arm
B: VP-16 was given on days 1-3 and CPT-11 on days 4-6. G-CSF was given to all patients daily on days 7-17. Twenty-seven patients were
entered randomly at the two arms. The major dose-limiting toxicities in arms A and B were granulocytopenia and diarrhoea. Transient
elevations of transaminases and bilirubin were observed in both arms. The degree of the toxicities did not differ between the two arms. The
maximum tolerated doses (MTDs) were 60 mg m-2 CPT-11 and 60 mg m-2 VP-16 in both arms. Ofthe 13 patients who received morethan two
cycles, two out of five achieved partial response (PR) at the first level of arm A and one out of four achieved PR at the second level of arm B.
We conclude that these schedules of sequential CPT-11 and VP-16 administration were inappropriate because of severe toxicities.
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Topoisomerase (Topo) inhibitors have played an important role in
cancer chemotherapies (Pommier, 1993).
hIinotecan (CPT- 1) is a new camptothecin derivative, which
has shown anti-tumour activity against several malignancies in
clinical trials (Fukuoka et al, 1992; Shimada et al, 1993).
Some investigators have reported that simultaneous exposure to
Topo I and II inhibitors results in a synergistic effect in vivo (Kano
et al, 1992). However, antagonistic effects of simultaneous
exposure to Topo I and II inhibitors have been reported by other
investigators (Kaufmann, 1991). The sequential administration of
camptothecin and etoposide (VP-16) separated by 6-8 h has been
reported to show an additive effect in vitro (Bertrand et al, 1991).
In some humantumourxenografts, the cytotoxicity ofdoxorubucin
is enhanced when it is sequentially administered 24 h after CPT-l 1
treatment, and tumour cells treated with CPT-11 show an increase
in Topo-II mRNA expression after 24 and 48 h (Kim et al, 1992).
These results suggest that sequential administration ofTopo I and
II inhibitors may enhance their anti-tumour effects.
We previously conducted a phase I trial of daily simultaneous
administration of CPT-l1 and VP-16, for 3 consecutive days, for
patients with refractory solid tumours (Karato et al, 1993).
Granulocytopenia was so severe that this regimen required
supportive therapy with granulocyte colony-stimulating factor
(G-CSF). The majordose-limiting toxicities (DLT) were diarrhoea
and weight loss. The recommended dose ofCPT-lIIVP-16 forthis
regimen with G-CSF support is 60/60 mg m-2 on days 1-3 every
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3 or 4 weeks. A phase II trial of this regimen for metastatic non-
small-cell lung cancer (NSCLC) without previous chemotherapy
has been conducted: 13 outof55 patients (23.6%) showed apartial
response (Goto et al, 1995).
To improve the therapeutic effect, we conducted a phase I trial
of sequential administration of CPT-l1 and VP-16 with G-CSF
support for patients with metastatic NSCLC. In the new regimen,
CPT-ll was given on days 1-3 and VP-16 on days 4-6 or VP-16
was given on days 1-3 and CPT-l1 on days 4-6. The aims of this
study were (a) to determine the maximum-tolerated doses (MTDs)
of sequentially administered CPT-11 and VP-16, (b) to determine
the toxicities ofsequentially administered CPT-l 1 and VP-16, and
(c) to observe the therapeutic activities ofthese regimens.
PATIENTS AND METHODS
Patient selection
Patients were enrolled in this study if they satisfied the following
criteria: (a) histological or cytological diagnosis of NSCLCs; (b)
stage IV disease; (c) no previous chemotherapy (recurrence after
surgical resection or previous localized radiotherapy was eligible);
(d) life expectancy ofatleast 12 weeks; (e) age <75 years; (f)perfor-
mance status of 0, 1, or 2 on the Eastern Cooperative Oncology
Group scale; (g) measurable or assessable disease; (h) adequate
bone marrow function (leucocyte count 2 4000gFi, platelet count
2 100 000 p1-1 and haemoglobin level 2 9 g dl-'), adequate renal
function (creatinine level < 1.5 mg dl-', creatinine clearance
.60 ml min-'), adequate hepatic function (total bilirubin level
. 1.5 mg dl-, transaminases 2 twice the normal upper limit) and
paO2 2 70 torr; (i) no concurrent malignancies; and (j) no medical
problems severe enough to preventcompliance with the protocol.
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Administration and evaluation
There were two arms in this protocol: in arm A, CP`T-11 was given
on days 1-3 and VP-16 on days 4-6; in arm B, VP-16 was given on
days 1-3 and CPT-11 on days 4-6. CPT-ll and VP-16 were each
dissolved in 250 ml of 5% glucose. CPT-l1, at various escalating
doses, was administered as a 90-min intravenous infusion. VP-16
was not escalated and was administered intravenously for 60 min at
a fixed dose of 60 mg m-2. The starting dose of CPT-l1 was
40 mg m-2 because it was reported that the recommended dose of
CPT-11/VP-16 with G-CSF support was 60/60mg m-2 on days 1-3
(Karato et al, 1993). The CPT-l1 dose level was escalated for
successive groups of patients in both arms: in arm A, the CPT-
11/VP-16 doses were 40/60, 60/60 and 80/60 mg m-2 and in arm B,
the VP-16/CPT-11 doses were 60/40, 60/60 and 60/80mg m-2.
Patients were assigned randomly to one of these arms at each dose
level. No intrapatient dose escalation was allowed. Antiemetics such
as granisetron or metoclopramide were administered on days 1-6.
To minimize granulocytopenia, all patients received G-CSF at a
daily dose of 2,g kg-' subcutaneously on days 7-17. Any episode
of diarrhoea was treated with 2 mg per body loperamide adminis-
tered orally every 6 h. We defined aDLT ifpatients experienced one
or more ofthe following: (a) grade 4 granulocytopenia lasting more
than 4 days with G-CSF support; (b) grade 4 thrombocytopenia; (c)
grade 3 or4 diarrhoea lasting more than 48 h with loperamide treat-
ment (if patients experienced diarrhoea, they were treated with
loperamide immediately) and (d) grade 3 non-haematological toxi-
city, excluding diarrhoea. Anaemia, alopecia, nausea and vomiting
were excluded from the evaluation of intolerable toxicity. It was
planned to enter three patients at each dose level of each arm and if
DLT was observed at one level of one arm, another three patients
were entered at that level. If more than one-third of the patients at
one level experienced DLT, we defined the dose as the MTD.
Patients who received more than two cycles were evaluated for
therapeutic efficacy. Toxicity and therapeutic efficacy were evalu-
ated according to the Japan Clinical Oncology Group common toxi-
city criteria (Tobinai et al, 1993) and World Health Organization
criteria (WHO, 1979) respectively. Patients continued to receive
their assigned treatment every 3 or 4 weeks, provided that they did
not develop progressive disease.
Pharmacokinetics
Heparinized blood samples (4 ml) for pharmacokinetic study were
obtained from the arm that was not being used for drug infusion.
Samples were obtained at the following times from arm A patients:
before CPT-11 infusion, 30 and 90 min after the start of CPT-11
infusion, and 5, 15 and 30 min and 1, 2, 3,4, 8, 12 and 22.5 h after
completion of CPT-11 infusion on day 1; and before VP-16 infu-
sion, 30 and 60 min after the start ofVP-16 infusion, and 5, 15 and
30 min and 1, 2, 4, 8, 12 and 23 h after completion of VP-16 infu-
sion on day 4. Samples from arm B patients were collected as the
same schedule as arm A patients but VP-16-related related samples
were collected on day 1 and CPT- 11-related samples were collected
on day 4. Each blood sample was centrifuged immediately and the
plasma was stored at -20°C until analysis. CPT-l1 and SN-38, an
active metabolite of CPT-I1, were assayed by high-performance
liquid chromatography (HPLC) with fluorescent detection, using a
procedure that allowed the simultaneous determination of both
compounds (Sumiyoshi et al, 1995). The detection limits for CPIT-
11 and SN-38 were 50 and 1 ng ml' respectively. The intra-assay
and interassay coefficients of variation (CV) for CPT-11 were less
Table 1 Patient characteristics and number of treatment courses
Characteristics
Number of patients 28
Number of assessable 27
Age Mean (range)
Arm A 59 (38-74)
Arm B 61 (40-70)
Sex (male:female)
Arm A 8:6
Arm B 8:6
pSa (0:1)
Arm A 6:8
Arm B 2:12
Histology (adeno:sqb)
ArmA 14:0
Arm B 13:1
aPerformance status on the Eastern Cooperative Oncology Group Scale;
bSquamous cell carcinoma.
Number of treatment courses
Level CPT-11NP-16 Number Number
(mg m-2) of courses of patients
40/60 Arm A 1 3
2 5
ArmB 1 4
2 3
11 60/60 Arm A 1 5
2 1
ArmB 1 2
2 3
3 1
Arm A: CPT-11 on days 1-3 and VP-16 on days 4-6; arm B: VP-16 on days
1-3 and CPT-11 on days 4-6.
than 5% and for SN-38 were less than 6%. VP-16 was assayed
using HPLC with ultraviolet detection, as reported by Holthus et al
(1981). The detection limit for VP-16 was 0.5 gg ml-'. The intra-
assay and interassay CVs were each less than 5%. Pharmacokinetic
parameters of CPT-11, SN-38 and VP-16 were determined on the
basis of model-independent methods. The area under the curve
(AUC) was calculated by the trapezoidal method, and total body-
clearance (Cl) was calculated as the dose divided by the AUC. The
AUC and mean residence time (MRT) were calculated by the
computer program MULTI (Yamaoka et al, 1981). Statistical
analyses between arm A and B results were performed using the
Wilcoxon rank-sum test and P values less than 0.05 were consid-
ered to indicate statistical significance. The correlations between
pharmacokinetic parameters (the AUC, Cm,, ofCPT-11, SN-38 and
VP-16) and the toxicity grade (granulocytopenia and diarrhoea)
were analysed using the Spearman rank correlation coefficient.
Statistical analyses were calculated using StatView-4.02 J (Abacus
Concepts, Berkeley, CA, USA).
RESULTS
Patient characteristics
Between October 1994 and August 1995 28 patients entered
this study. One patient was ineligible because of infection.
Histologically, 27 patients had adenocarcinoma and one patient
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Table 2 Haematological toxicity at the first course
(a) Level (CPT-11 / VP-16: 40 / 60 mg/m-2)
Arm A grade' Arm B grade
0-1 2 3 4 0-1 2 3 4
Leucopenia 4 1 3 0 5 1 1 0
Granulocytopenia 5 0 1 2 3 1 2 1
Anaemia 5 3 0 - 6 1 0
Thrombocytopenia 8 0 0 0 7 0 0 0
(b) Level II (CPT-11 / VP-16: 60 / 60 mg m-2)
Arm A gradea Arm B grade
0-1 2 3 4 0-1 2 3 4
Leucopenia 3 1 2 0 3 0 1 2
Granulocytopenia 3 0 2 1 3 0 1 2
Anaemia 5 1 0 - 2 3 1
Thrombocytopenia 6 0 0 0 5 0 0 1
Arm A: CPT-11 on days 1-3 and VP-16 on days 4-6; arm B: VP-16 on days
1-3 and CPT-11 on days 4-6; aJCOG toxicity criteria.
Table 3 Non-haematological toxicity at the first course
(a) Level (CPT-11 / VP-16: 40 / 60 mg/m-2)
Arm A gradea Arm B grade
0-1 2 3 4 0-1 2 3 4
Nausea and vomiting 4 4 0 - 3 4 0 -
Diarrhoea 6 1 1 0 4 3 0 0
Total bilirubin 7 0 1 0 5 1 1 0
Transaminases 6 1 1 0 5 2 0 0
Alopecia 6 2 - - 5 2 - -
Infection 7 1 0 0 7 0 0 0
Skin rash 8 0 0 0 7 0 0 0
(b) Level II (CPT-11 / VP-16: 60 / 60 mg m-2)
Arm A gradea Arm B grade
0-1 2 3 4 0-1 2 3 4
Nausea and vomiting 4 2 0 - 4 1 1 -
Diarrhoea 3 1 1 1 1 3 2 0
Total bilirubin 4 1 1 0 4 1 1 0
Transaminases 4 1 1 0 4 0 2 0
Alopecia 5 1 - - 3 3 - -
Infection 5 1 0 0 5 0 0 1
Skin rash 5 0 1 0 6 0 0 0
Arm A: CPT-11 on days 1-3 and VP-16 on days 4-6; arm B: VP-16 on days
1-3 and CPT-11 on days 4-6; aJCOG toxicity criteria.
had squamous cell carcinoma. Twenty-seven patients were assess-
able for toxicity and received one to three courses (arm A, mean =
1.4 and total = 20 courses; arm B, mean = 1.6 and total = 21
courses). The characteristics ofthe patients who entered this study
and the treatment courses per dose are listed in Table 1.
Toxicity during the first course
Haematological toxicity
At level I, two of the eight patients in arm A experienced grade 4
granulocytopenia that lasted for 2 days in one patient and 5 days in
the other. One ofthe seven patients in arm B experienced grade 4
granulocytopenia that lasted for 2 days. At level II, one of the six
patients in arm A experienced grade 4 granulocytopenia that lasted
for 2 days, and two ofthe six patients in arm B experienced grade
4 granulocytopenia that lasted for 5 and 8 days. One of the six
patients in arm B experienced grade 4 thrombocytopenia at level
II. This patient suffered severe pneumonia with myelosuppression,
and died on day 15 after drug administration. The patient did not
have diffuse bone metastases, which might have caused latent
myelosuppression. Granulocytopenia was a DLT at level I of arm
A and level II of arm B. There was no remarkable difference in
haematological toxicities between the two arms (Table 2).
Non-haematological toxicity
Transient liver abnormalities were observed at level I and II of
both arms. Three outofeightpatients treated atlevel I experienced
hepatic toxicities (Table 3). One out ofeight patients showed grade
3 elevation of total serum bilirubin with grade 1 elevation of
transaminases (peaklevel, 3.0 mg ml-') between day 7 and day 14.
In a second patient, elevation ofgrade 3 transaminases (peak level,
aspartate aminotransferase (AST) 50 IU 1-, alanine aminotrans-
ferase (ALT) 136 IU 1-') without elevation of bilirubin was
observed between day 7 andday 11. Finally, athird patient showed
grade 2 elevation of transaminases without elevation of bilirubin
between day 2 and day 11. At the same level of arm B, one out of
seven patients showed grade 3 elevation of bilirubin (peak level,
2.3 mg ml-') between days 7 and 11, with grade 1 elevation of
transaminases. Two other patients experienced transient grade 2
elevation of transaminases without elevation of bilirubin. These
liver toxicities were transient, reversible and therefore tolerable.
At level II ofarm A, two patients experienced hepatotoxicity. One
out of six patients showed grade 3 elevation of bilirubin (peak
level, 2.9 mg ml-') with grade 3 elevation of transaminases (peak
level, AST 380 IU 1-1, ALT 547 LU 1-1) on day 7, which disap-
peared on day 14. Anotherpatientexperienced grade 2 elevation of
transaminases with grade 2 elevation of bilirubin. At the same
level ofarm B, one out ofsix patients showed grade 3 elevation of
transaminases without elevation of bilirubin, which was observed
between day 7 andday 14. A secondpatient showed grade 2 eleva-
tion of bilirubin with grade 3 elevation of transaminases. This
accompanied severe myelosuppression, and the patient died of
severe pneumonia on day 15; this was considered to be a treat-
ment-related death. All patients with grade 3 elevation ofbilirubin
or transaminases also experienced grade 4 granulocytopenia. Two
out ofeight patients at level I of arm A, four out of seven patients
at level I ofarm B, three outofsix patients at level II ofarm A and
four out of six patients at level II ofarm B experienced grade 1 or
2 diarrhoea on day 7 that lasted 4 or5 days. Grade 3 diarrhoea with
grade 3 granulocytopenia and elevation ofbilirubin was observed
in one ofeight patients at level I of arm A and lasted for one day.
At level II of arm A, one out of six patients experienced grade 3
diarrhoea (duration, 3 days) with grade 3 granulocytopenia, and
one out of six patients experienced grade 4 diarrhoea (duration
5 days). At the same level of arm B, two out of six patients
experienced grade 3 diarrhoea (duration 1 and 8 days respec-
tively). One patient at level II of arm B died of grade 4 infection
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listed inTable4a and b. The mean AUCs ofCPT-l1 and SN-38 were
higherin arm B than in arm A atCPT-11/VP-16 40/60mg rn-2 (mean
± s.d., ng h ml-'; CPT-l1, arm A, 1015.1 + 294.1, arm B, 1798.2 +
318.6 (P = 0.02) and SN-38, arm A, 26.4 + 12.8, arm B, 73.0 ± 53.6
(P = 0.04). At 60/60mg m-2, the mean AUC ofSN-38 was higher in
arm B than in arm A (mean± s.d. ng hml-'); arm A, 62.2± 15.9, arm
B, 108.3 + 28.2 (P = 0.04). There was no significant difference
betweenthetwoarms ateachlevel inthemean C ofCPT-1l orSN-
nma
38. Andtherewerenosignificantrelationshipsbetweenthepharmaco-
kinetic parameters andthe grades ofthe toxicities.
DISCUSSION
Figure 1 Mean plasma concentrations of CPT-11 and SN-38 at CPT-11 40
and VP-16 60 mg m-2. 0, Arm A (n = 4); A, arm B (n = 4). Error bars s.d.
7 10
E
0'
co
0 5 10 15 20 25
Time (h)
Figure 2 Mean plasma concentrations of VP-16 at CPT-11 40 and
VP-16 60 mg m-2. *, Arm A (n = 4); A, arm B (n =4). Error bars ± s.d.
with myelosuppression and grade 3 diaffhoea, nausea and
vomiting, which was considered to be a treatment-related death
(TRD). At level II of arm A, one out of six patients experienced
grade 3 skin rash onday 3. There was no remarkable difference in
non-haematological toxicities between the two arms. Three out of
sixpatients at level II ofarm A and two out ofsix patients at level
II of arm B experienced DLT. Therefore, we considered that level
II ofarms A and B was the MTD.
Treatment courses and therapeutic efficacy
A total of 12 out of 27 patients received two courses and one
patient received three. The reasons for stopping the treatment
were: intolerable toxicity, eight patients (infection, one patient;
diarrhoea, two; liver dysfunction, four; and TRD, one); disease
progression, four; patient refusal, two. At level I of arm A, two
patients with transient elevations of bilirubin and transaminases
during the first course showed the same liver toxicities during the
second course. Of the 13 patients who received more than two
courses, two out offivepatients atlevel I ofarm A and one offour
at level II ofarm B experiencedpartial responses.
Pharmacokinetics
Plasmasamples wereobtainedfirom 16patientsduringthefirstcourse.
The meanplasmaconcentration vs time curves ofCPT-I , SN-38 and
VP-16 at CPT-11/VP-16 40/60 mg mr-2 ar-e shown inFigures I and 2.
The pharmacokinetic parameters derived from the plotted data are
There were few reports on the phase I trials using combination
chemotherapy of Topo I and Topo H inhibitors (Eckardt et al,
1993; Schneider et al, 1994). They could not escalate the dose
because ofgranulocytopenia at the early steps. A phase I study of
combination chemotherapy in which topotecan (CPT) was given
by continuous infusion on days 1-3 and VP-16 was given over 2 h
on days 7-9 has been reported previously (Eckardt et al, 1993).
Two out of six patients with previous heavy therapy experienced
grade 4 granulocytopenia at the first dose level (CPT, 0.17 mg m-2
day-' and VP-16, 100 mg m-2 day-1). In addition, other clinicians
have reported a phase I study in which CPT was given by contin-
uous infusion on days 1-3 and doxorubicin was given over 2 h on
day 5 (Schneider et al, 1994). Two out of six patients experienced
grade 4 granulocytopenia at the second dose level (CPT,
0.5 mg m-2 day-1 and doxorubicin, 45 mg m-2). In both of these
studies ofthe sequential administration ofTopo I and II inhibitors,
haematological toxicities were severe.
In the phase I trial of simultaneous administration for three
consecutive days with G-CSF support, one out of six patients at
the doses of 40 mg m-2 of CPT-11 and 60 mg m-2 of VP-16, and
three of 13 patients at the doses of 60 and 60 mg m-2 experienced
grade 4 granulocytopenia (Karato et al, 1993). In another study,
60 mg m-2 of CPT-11 was administered on days 1, 8 and 15, and
80 mg m-2 of VP-16 was administered on days 1-3 with G-CSF
support, none offive patients experienced grade 3 to 4 leucopenia
(Masuda et al, 1994). Although these studies were not a random-
ized comparative study, granulocytopenia seems to be more severe
in sequential drug administration.
During the simultaneous administration of 60/60 mg m-2 of
CPT-l and VP-16 for three consecutive days, 1 out of 13 patients
and 10 out of61 patients experienced grade 3 or 4 diarrhoea in the
previous phase I and II study respectively (Karato et al, 1993;
Goto et al, 1995). Diarrhoea seemed to be a dose-dependent toxi-
city in this administration schedule and more severe in the sequen-
tial administration of the two drugs than in the simultaneous
administration ofthe drugs.
The hepatic toxicities in our study may suggest that liver
impairment may prolong bone marrow exposure leading to inten-
sified and prolonged myelosuppressions. Otherwise, liver impair-
ment might co-segregate with myelosuppression as a sign of
severe toxicity. Hepatic toxicities were not dose-dependent. In
contrast, 5 out of 61 patients treated simultaneously with
60 mg m-2 day-' of CPT-l1 and VP-16 experienced more than
grade 2 elevation of transaminases in the previous phase II trial
(Goto et al, 1995). These elevations of transaminases were tran-
sient. Four out ofthese five patients showed transient co-elevation
of bilirubin. Grade 2 or 3 transient elevations of bilirubin were
observed in 8 out of 61 patients (Goto et al, 1995). Therefore,
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Table 4 Pharmacokinetic parameters of CPT-11, SN-38 and VP-16
(a) CPT-11 40 mg m-2 / VP-16 60 mg m-2
AUC (ng h ml-') MRT (h) Cm.x (ng ml-') T,, (h) Total clearance (I h-' m-2)
CPT-li1 (mean ± s.d.)
Arm A (n= 4) 1015.1 ± 294.1 3.3± 1.2 422.3± 119.7 1.53 ± 0.04 41.8± 11.1
Arm B (n = 4) 1798.2 ± 318.6' 5.7 ± 0.4' 389.8 ± 86.2 1.26 ± 0.51 22.7 ± 3.7
SN-38
Arm A (n = 4) 26.4 ± 12.8 2.3 ± 1.2 10.3 ± 2.6 1.72 ± 0.21 -
Arm B (n = 4) 73.0 ± 53.6' 4.8± 2.1 12.5 ± 3.9 1.98 ± 0.37 -
VP-16
ArmA(n=4) 39.9 ± 3.1 4.2 ± 0.4 10.3 ± 1.4 1.25 ± 0.18 1.5 ± 0.1
Arm B(n=4) 46.1 ±4.9 4.6±0.8 11.8±0.9 1.06±0.13 1.3±0.2
(b) CPT-11 60 mg m-2 / VP-16 60 mg m-2
AUC (ng h ml-') MRT (h) Cm,, (ng ml-') TM,,, (h) Total clearance (I h-1 m-2)
OPT-il1 (mean ± s.d.)
Arm A (n = 4) 2050.1 ± 350.6 5.0 ± 0.8 502.4 ± 97.9 1.54 ± 0.14 29.9 ± 5.7
Arm B (n = 4) 2251.6 ± 211.4 5.4 ± 0.3 701.8± 150.2 1.58± 0.17 26.8 ± 2.4
SN-38
ArmA(n=4) 62.2± 15.9 4.2±0.9 14.3±3.1 1.61 ±0.17 -
Arm B (n = 4) 108.3± 28.2' 6.9 ± 2.0' 16.3 ± 1.2 1.83± 0.41 -
VP-16
ArmA(n=4) 52.8±10.4 4.7±0.4 14.2±2.8 1.04±0.08 1.2±0.2
Arm B(n=4) 43.7±5.8 4.2 ± 0.6 11.8± 2.1 1.19 ± 0.24 1.4 ± 0.2
Arm A: CPT-11 on days 1-3 and VP-16 on days 4-6; arm B: VP-16 on days 1-3 and CPT-11 on days 4-6; *P< 0.05.
hepatic toxicities seem to be increased in patients treated with the
sequential administration of CPT- 11 and VP-16 compared with
patients treated with the simultaneous administration of the two
drugs. Both CPT- 11 and VP-16 are metabolized in the liver
(Kaneda and Yokokura, 1990; Hande, 1992). The schedule of
CPT-l 1 and VP-16 administration on 6 consecutive days may have
caused these hepatic toxicities via any drug-drug interactions.
In the pharmacokinetic analysis, the plasma concentrations of
CPT-11 and SN-38 at level I of arm B seemed to decrease more
slowly than at the same level of arm A. This difference was not
clear at the higher dose level, perhaps because ofthe small sample
size and the large interpatient variabilities in the pharmacokinetics
ofCPT-11 and SN-38. The AUCs ofCPT-11 and SN-38 are signif-
icantly higher in arm B than in arm A. It is necessary to conduct a
preclinical study to clarify the underlying mechanism.
Overall, DLT was observed in one out ofeight patients at level I
ofarm A, three out ofsix patients at level II ofarm A and two out
of six patients at level II of arm B. The DLTs were granulocyto-
penia and diarrhoea. We conclude that the level II doses ofarms A
and B are the MTDs. The sample size of this study was too small
to detect differences in toxicities between the two arms. However,
because of severity oftoxicities observed, it would not be defend-
able to enlarge the patient cohort.
In conclusion, the MTDs of sequentially administered CPT-l1
and VP-16 each over 3 days with G-CSF support were 60 mg m-2
day-' respectively. No differences in toxicities were seen in the
differences of the sequence of administration. The major DLTs
were granulocytopenia and diarrhoea. Transient elevations of
transaminases and bilirubin were observed. We conclude that the
regimens caused too severe toxicities to be considered for further
assessment. At present, the combination ofTopo I and II inhibitors
are not clinically easy, although preclinical results are rather
encouraging.
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